Premium
P4‐016: MCLENA‐1: A PHASE II CLINICAL TRIAL FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LENALIDOMIDE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE; TRIAL DESIGN AND RATIONALE
Author(s) -
Decourt Boris,
Fulkerson Nadia,
Burns Alana,
Lee Garam,
St Rose Tessa,
Hartley Katurah,
Dardis Christopher,
Wilson Jeffrey,
Sabbagh Marwan N.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.3675
Subject(s) - lenalidomide , tolerability , medicine , placebo , oncology , clinical endpoint , clinical trial , pathology , adverse effect , multiple myeloma , alternative medicine